The assessment of clinicopathological features, therapy pattern and survival benefit of 162 gastric cancers with liver metastases

Hepato-Gastroenterology

Volumn 60, Issue 123, 2013, Pages 628-632

  Li, Jian ^a   Lu, Ming ^a   Li, Jie ^a   Zhang, Xiaodong ^a   Li, Yan ^a   Zhang, Xiaotian ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chemotherapy; Extrahepatic metastases; Gastric cancer with liver metastases; Local therapy; Survival

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879564716     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12729     Document Type: Article

References (38)

1. Thun MJ, DeLancey JO, Center MM, et al.: The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31:100-110.
2. Sakamoto Y, Ohyama S, Yamamoto J, et al.: Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surg 2003; 133:507-511. (Pubitemid 36638222)
3. Okano K, Maeba T, Ishimura K, et al.: Hepatic resection for metastatic tumours from gastric cancer. Ann Surg 2002; 235:86-91. (Pubitemid 34062403)
4. Zacheri J, Zacheri M, Scheuba C, et al.: Analysis of hepatic resection of metastases originating from gastric adenocarcinoma. J Gastrointest Surg 2002; 6:682-689. (Pubitemid 40433486)
5. Kunieda K, Saji S, Sugiyama Y, et al.: Evaluation of treatment for synchronous hepatic metastases from gastric cancer with special reference to long-term survivor. Surg Today 2002; 32:587-593. (Pubitemid 34754262)
6. Dickson JL, Cunningham D: Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004; 16(3):255-263. (Pubitemid 38372175)
7. Aloia TA, Vauthey JN, Loyer EM, et al.: Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141:460-466; discussion 466-467.
8. van Dam RM, van de Poll MCG, Greve JWM, et al.: Hepatectomy for colorectal cancer liver metastases: effects of multidisciplinary regional collaboration and extended indications. Eur J Gastroenterol Hepatol 2005; 17(1):A43.
9. Kokudo N, Tada K, Seki M, et al.: Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001, 181:153-159. (Pubitemid 32406310)
10. Hirai I, Kimura W, Fuse A, et al.: Surgical management for metastatic liver tumors. Hepatogastroenterology 2006; 53:757-763. (Pubitemid 44682997)
11. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al.: Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187:487-493. (Pubitemid 28506854)
12. Harrison LE, Brennan MF, Newman E, et al.: Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997; 121:625-632. (Pubitemid 27251901)
13. Kirchhoff T, Chavan A, Galanski M: Chemoembolization of hepatic metastases from intestinal neuroendocrine tumours. Eur J Gastroenterol Hepatol 2000; 12(2):141-143. (Pubitemid 30166676)
14. Kim HR, Cheon SH, Lee KH, et al.: Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia 2010; 26:305-315.
15. Kunieda K, Saji S, Sugiyama Y, et al: Evaluation of treatment for synchronous hepatic metastases from gastric cancer with special reference to long-term survivor. Surg Today 2002; 32:587-593. (Pubitemid 34754262)
16. Marrelli D, Pedrazzani C, Corso G, et al.: Different pathological features and prognosis in gastric cancer patients coming from high-risk and low-risk areas of Italy. Ann Surg 2009; 250(1):43-50.
17. Zheng H, Takahashi H, Murai Y, et al.: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 2007; 60:273-277. (Pubitemid 46447742)
18. Hofmann M, Stoss O, Shi D, et al.: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797-805. (Pubitemid 351724903)
19. Allgayer H, Babic R, Gruetzner KU, et al.: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18(11):2201-2209. (Pubitemid 30350211)
20. Bang YJ, Van Cutsem E, Feyereislova A, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
21. Li C, Yan M, Chen J, et al.: Survival benefit of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis. J Gastrointest Surg 2010; 14: 282-288.
22. Fujisaki S, Tomita R, Nezu T, et al.: Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 2001; 48:892-894. (Pubitemid 32619707)
23. Fujitani K, Yang HK, Kurokawa Y, et al.: Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol 2008; 38:504-506.
24. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371(9617):1007-1016. (Pubitemid 351392040)
25. Folprecht G, Gruenberger T, Bechstein WO, et al.: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11(1):38-47.
26. Miki Y, Fujitani K, Hirao M, et al.: Significance of surgical treatment of liver metastases from gastric cancer. Anticancer Res 2012; 32(2):665-670.
27. Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, et al.: Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature. Gastric Cancer 2012; 15(2):131-136.
28. Hirasawa T, Asahara S, Fujisaki S, et al.: Transcatheter arterial chemoembolization (TACE) using degradable starch microspheres (DSM) for metastatic liver tumors in patients with gastric cancer. Nippon Shokakibyo Gakkai Zasshi 2008; 105:367-372.
29. Ueda K, Iwahashi M, Nakamori M, et al.: Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 2009; 394:647-653.
30. Makino H, Kunisaki C, Izumisawa Y, et al.: Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res 2010; 30:2367-2376.
31. Sumpter K, Harper-Wynne C, Cunningham D, et al.: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92(11):1976-1983. (Pubitemid 40897418)
32. Ryu MH, Kang YK: ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther 2009: 9(12):1745-1751.
33. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24(31):4991-4997. (Pubitemid 46631401)
34. Dank M, Zaluski J, Barone C, et al.: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19(8):1450-1457.
35. Sahara S, Kawai N, Sato M, et al.: Prospective Evaluation of Transcatheter Arterial Chemoembolization (TACE) with Multiple Anti-Cancer Drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) Compared with TACE with Epirubicin for Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol (online publ.) 2012; Feb 23.
36. Poggi G, Montagna B, Melchiorre F, et al.: Hepatic intraarterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. Anticancer Res 2011; 31(11):3927-3933.
37. Rimassa L, Santoro A: Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 2009; 9(6):739-745.
38. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23(36):9441-9442.